Gartisertib

Gartisertib (VX-803) is an ATP-competitive, orally active, and selective ATR inhibitor, with a Ki of 50 of 8 nM. Antitumor activity[1][2].

Product Specifications

CAS Number

[1613191-99-3]

Product Name Alternative

VX-803; M4344; ATR inhibitor 2

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

ATM/ATR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/atr-inhibitor-2.html

Purity

99.77

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C(C1=C2N=CC(F)=CN2N=C1N)NC3=C(N4CCC(C(N5CCN(C6COC6)CC5)=O)CC4)C(F)=CN=C3

Molecular Formula

C25H29F2N9O3

Molecular Weight

541.55

Precautions

H302, H315, H319, H335

References & Citations

[1]Frank T. Zenke, et al. Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy. Experimental and Molecular Therapeutics.|[2]Gorecki L, et al. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620) : Clinical candidate for cancer therapy. Pharmacol Ther. 2020 Feb 26:107518.